Get Tirzepatide Online — From $179/Month
Real Tirzepatide prescribed by licensed US clinicians. ~22.5% body weight body weight on average. Dual-agonist GLP-1/GIP. Currently the most powerful approved weight-loss medication.
✓ No insurance needed · ✓ Ships in 5-7 days · ✓ Cancel anytime
Tirzepatide is the first FDA-approved dual GLP-1 / GIP receptor agonist, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. It produces the largest weight loss of any approved obesity medication — averaging 22.5% body weight reduction over 72 weeks at the 15 mg dose.
Overview
Tirzepatide was developed by Eli Lilly and approved as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for weight loss in November 2023. In 2024 it received an additional indication for obstructive sleep apnea in adults with obesity. A 2025 expansion approved Zepbound vials sold direct via LillyDirect for $349/month.
Tirzepatide is a 39-amino-acid peptide that activates both the GLP-1 and the GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is the second major incretin hormone alongside GLP-1; combining the two appears to produce stronger appetite suppression and metabolic benefit than GLP-1 alone.
How Tirzepatide Works
Tirzepatide hits two receptors:
- GLP-1 receptor — reduces appetite, slows gastric emptying, increases insulin (glucose-dependent), reduces glucagon
- GIP receptor — additional insulin potentiation, possible direct effects on adipose tissue and brain reward circuits
Adding GIP appears to amplify the appetite-suppressing effect and may reduce some GLP-1 side effects (including possibly nausea). Trial data show tirzepatide produces about 50% more weight loss than equivalent doses of semaglutide alone.
Dosing & Schedule
Tirzepatide is titrated over 20+ weeks. Standard escalation:
- Weeks 1-4: 2.5 mg/week
- Weeks 5-8: 5 mg/week
- Weeks 9-12: 7.5 mg/week
- Weeks 13-16: 10 mg/week
- Weeks 17-20: 12.5 mg/week
- Weeks 21+: 15 mg/week (maximum)
Many patients reach a satisfactory response at 10 mg or 12.5 mg and never escalate to 15 mg.
Effectiveness — Trial Data
SURMOUNT-1 trial (72 weeks, n=2,539 adults with obesity, no diabetes):
- 15 mg group: 20.9% average weight loss (22.5% at 72 weeks of full dose)
- 10 mg group: 19.5%
- 5 mg group: 15.0%
- Placebo: 3.1%
- 57% of 15 mg users lost ≥20%; 36% lost ≥25%
Side Effects
Common adverse events (SURMOUNT-1):
- Nausea (29-39% by dose)
- Diarrhea (21-23%)
- Constipation (12-17%)
- Vomiting (11-16%)
- Decreased appetite (universal, intended)
Discontinuation due to side effects: 4.3-7.1% across dose groups. Tirzepatide carries the same boxed warning for medullary thyroid carcinoma as semaglutide.
Cost — How Much Tirzepatide Costs in 2026
Tirzepatide pricing:
- Zepbound list price: $1,069/mo (autoinjector pens)
- LillyDirect Zepbound vials: $349/mo (2.5 mg) to $499/mo (10 mg+)
- Mounjaro list price: $1,069/mo
- Insurance copay: typically $25-150/mo when covered
- Compounded tirzepatide via telehealth: from $249/mo
Who Is Tirzepatide For?
Tirzepatide is FDA-approved for:
- Adults with BMI ≥30 (Zepbound)
- Adults with BMI ≥27 with weight-related comorbidity (Zepbound)
- Adults with type 2 diabetes (Mounjaro)
- Adults with obstructive sleep apnea + obesity (Zepbound, 2024 expansion)
Tirzepatide Alternatives
If tirzepatide is not the right fit:
- Semaglutide — somewhat less effective but more affordable
- Retatrutide — pipeline triple-agonist with even stronger results
- CagriSema — pipeline combination drug